Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies

Siu Chiu Chan(University of Minnesota), Scott M. Dehm(University of Minnesota)
Nucleic Acids Research
April 23, 2015
10.1093/nar/gkv262
Cited by 151

Related Papers

Ligand-independent Androgen Receptor Activity Is Activation Function-2-independent and Resistant to Antiandrogens in Androgen Refractory Prostate Cancer Cells
|Journal of Biological Chemistry|2006|113
Hepatocyte nuclear factor-1β regulates Wnt signaling through genome-wide competition with β-catenin/lymphoid enhancer binding factor
|Proceedings of the National Academy of Sciences|2019|26
Evolution of <i>AR</i> and Non- <i>AR</i> Alterations in ctDNA of Patients with Metastatic Prostate Cancer Treated in the Phase III Alliance A031201 Trial
|Clinical Cancer Research|2026|1
Supplementary Materials and Methods from Targeting a Single Alternative Polyadenylation Site Coordinately Blocks Expression of Androgen Receptor mRNA Splice Variants in Prostate Cancer
|Unknown|2023|0
Supplementary Materials and Methods from Targeting a Single Alternative Polyadenylation Site Coordinately Blocks Expression of Androgen Receptor mRNA Splice Variants in Prostate Cancer
|Unknown|2023|0